SGLT2 Inhibitors May Slow Aging by Clearing Senescent Cells
Diabetes drugs like empagliflozin show surprising anti-aging effects โ mimicking caloric restriction and reducing senescent cell burden.
20 articles
Diabetes drugs like empagliflozin show surprising anti-aging effects โ mimicking caloric restriction and reducing senescent cell burden.
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
Mice lacking the HDAC9 gene gained less fat with age, accumulated fewer senescent cells, and showed improved mitochondrial respiration in adipose tissue.
New cryo-EM structures reveal how LYCHOS protein senses cholesterol levels to regulate mTORC1 signaling, offering drug targets for aging.
Blocking mTOR forces cancer cells to rewire cholesterol uptake and transport, revealing new drug targets when combined with rapamycin.
New research reveals how regular physical activity directly prevents and slows progression of major age-related diseases.
New England Journal review explores the expanding therapeutic potential of GLP-1 drugs beyond diabetes treatment.
Researchers explore targeted immune strategies to improve pancreatic islet transplant success rates for diabetes treatment.
Researchers shift from systemic B-cell targeting to localized immune control, potentially improving transplant success rates.
A mouse study reveals how aging and poor diet synergistically disrupt liver thyroid hormone metabolism, accelerating fatty liver disease โ and why resmetirom may help.
New research reveals how mitochondrial metabolism regulates dendritic cells' ability to activate anti-tumor immunity.
New study shows DunedinPACE aging biomarker can predict who will develop metabolic syndrome years in advance, outperforming other epigenetic clocks.
NIH study identifies metabolic mechanism behind controversial skin condition and demonstrates successful treatment with mitochondrial complex I inhibitors.
New research reveals pulsed electromagnetic field therapy selectively enhances ATP-linked mitochondrial respiration, pointing to a specific cellular energy mechanism.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
Inclisiran safely reduced LDL cholesterol by 28% in adolescents with familial hypercholesterolemia, offering hope for early intervention.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
Large NHANES study reveals metabolic syndrome causes measurable acceleration in epigenetic aging clocks, offering new targets for intervention.
Three-month romosozumab protocol offers pragmatic solution for osteoporosis treatment with potentially improved patient outcomes.
New research examines whether the cholesterol-lowering drug inclisiran could benefit pediatric patients with genetic high cholesterol.